Coronavirus (COVID-19) updates for UC San Diego Health patients and visitors. Learn More

Menu
Search

UC San Diego Selected as Study Site for National Research Network

 

April 13, 2011  |  

27 institutions looking for ways to boost immune system to fight cancer

The University of California, San Diego School of Medicine is among 27 research institutions selected across North America to be a part of the Cancer Immunotherapy Trials Network (CITN), funded by the National Cancer Institute (NCI).  The CITN will establish a network of top academic immunologists to conduct multicenter research on agents that boost patients’ own immune systems to fight their cancer. 

Thomas Kipps

Dr. Thomas Kipps will lead the CITN site at UC San Diego Moores Cancer Center.

"We are very proud to participate in CITN, which includes sites with some of the foremost research on cancer immunotherapy in the nation,” said Thomas J. Kipps, MD, PhD, professor of medicine at UCSD School of Medicine and deputy director of UC San Diego Moores Cancer Center.  “Participation in the network is a two-way street whereby other institutions receive access to trials created at UC San Diego and, alternatively, our patients receive novel advanced investigational treatments created elsewhere in the country. In other words, everyone benefits from this type of arrangement."

By coordinating the efforts of academia, industry and philanthropic foundations, the CITN is charged with accelerating the development of promising agents that have already been discovered but are not currently used to treat patients with cancer. 

Institutions applied for member-site status in an open competition followed by a two-stage evaluation process conducted by the NCI. Candidates were evaluated on the experience, participation and collaboration of the investigators and their institutions in immunotherapy trials and their ability to provide laboratory expertise in tumor immunology to support the trials.

In September 2010, the Fred Hutchinson Cancer Research Center in Seattle received funding to serve as the network’s Central Operations and Statistical Office (COSC). The COSC will provide overall leadership and infrastructure for the network.  In addition to UC San Diego, the participating institutions include: Baylor University, Case Western Reserve University, Dana Farber Cancer Center, Dartmouth-Hitchcock Norris Cotton Cancer Center, Duke University Medical Center, Emory University, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center, Memorial Sloan-Kettering Cancer Center, New York University Cancer Institute, Ohio State University, Providence Cancer Center, Roswell Park Cancer Center, Rush University Cancer Center, Stanford University, University of California, San Francisco, University of Chicago, University of Miami, University of Minnesota, University of Pennsylvania, University of Pittsburgh, University of Toronto Ontario Cancer Institute, University of Virginia, University of Wisconsin, and Yale University.

# # #

Media Contact: Kim Edwards, 619-543-6163, kedwards@ucsd.edu


Related Specialties



Media Contact

Share This Article


Related News

3/26/2020
Researchers at University of California San Diego School of Medicine are launching a pair of studies to answer critical questions regarding the roles COVID-19 may play in breast milk and pregnancy.
3/24/2020
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients w ...
3/20/2020
Partnering with five diagnostics manufacturers, UC San Diego is significantly ramping up testing for COVID-19, projecting capacity to complete up to 1,500 tests daily within two to three weeks.
3/18/2020
New study finds gene therapy improved cardiac, muscle and liver function in Danon disease mouse models.



Follow Us